Novel assay provides earlier, faster diagnosis and targeted treatment of sepsis.
Patented pharmaceutical peptide targets currently untreatable biofilm infections. Innovative substrate-independent peptide coatings maintain sterile medical devices and implants.
The crisis: Widespread and deadly*
cases of sepsis
sepsis deaths a year
incidence of sepsis in COVID deaths
10 to 1000x
more resistant to most antibiotics
drugs approved for biofilms
of all infections are biofilms
* Data on file
Large Addressable Global Markets
With NO efficient clinical solutions (unmet medical needs)
In the early diagnosis of sepsis and treatment of biofilm Infections
Extensive Intellectual Property
Portfolio of both Diagnostics and Therapeutics
Near-term Revenue Models
With multiple corporate partnership targets
For enhanced shareholder liquidity
Experienced Management Team
With proven track records in med-tech and biopharma
As sepsis and antibiotic-resistant infections continue to be a severe burden on the healthcare system, Asep Inc. offers excellent investment potential, with a combined market of $179 billion, and robust growth.
$41.9B Global Antibiotic Market CAGR: 3%
Global MRSA Market*
Global Device Infection Market
Global CRS Market
Global Ear Infection Market
Global Bacterial Vaginosis
Global Urinary Tract Infections
Global Wound Care Market
$1.0B Global Sepsis Dx CAGR: 8.5%
Click the link below to view our archived webinars.